Consolidated statement of cash flows
Download(XLS, 36 KB)| January 1 to December 31, € in millions | Note | 2021 | 2020 |
|---|---|---|---|
| Operating activities | |||
| Net income | 2,819 | 2,823 | |
| Adjustments to reconcile net income to cash and cash equivalents provided by operating activities | |||
| Depreciation and amortization | 18, 19, 20, 31 | 2,667 | 2,715 |
| Change in deferred taxes | 11 | 84 | 43 |
| Loss / Gain on sale of fixed assets and of investments and divestitures | 2 | 42 | -60 |
| Changes in assets and liabilities, net of amounts from businesses acquired or disposed of | |||
| Trade accounts and other receivables | 16 | 87 | -26 |
| Inventories | 17 | -105 | -527 |
| Other current and non-current assets | 18 | -320 | -252 |
| Accounts receivable from / payable to related parties | -10 | 13 | |
| Trade accounts payable, provisions and other short-term and long-term liabilities | 21, 22 | -154 | 1,819 |
| Liabilities for income taxes | -32 | 1 | |
| Net cash provided by operating activities | 5,078 | 6,549 | |
| Investing activities | |||
| Purchases of property, plant and equipment and capitalized development costs | 19 | -2,047 | -2,406 |
| Proceeds from sales of property, plant and equipment | 30 | 40 | |
| Acquisitions and investments and purchases of intangible assets | 2, 34 | -999 | -720 |
| Proceeds from sale of investments and divestitures | 2 | 199 | 75 |
| Net cash used in investing activities | -2,817 | -3,011 |
Consolidated statement of cash flows
Download(XLS, 36 KB)| January 1 to December 31, € in millions | Note | 2021 | 2020 |
|---|---|---|---|
| Financing activities | |||
| Proceeds from short-term debt | 23 | 3,279 | 282 |
| Repayments of short-term debt | 23 | -688 | -2,529 |
| Proceeds from long-term debt | 23 | 458 | 61 |
| Repayments of long-term debt | 23 | -3,028 | -1,438 |
| Repayments of lease liabilities | 31 | -880 | -937 |
| Proceeds from the issuance of bonds | 24 | 2,714 | 4,577 |
| Repayments of liabilities from bonds | 24 | -2,253 | -937 |
| Repayments of convertible bonds | 25 | – | -400 |
| Payments for the share buy-back program of Fresenius Medical Care | 28 | – | -366 |
| Payments for the Accounts Receivable Facility of Fresenius Medical Care | 23 | – | -374 |
| Proceeds from the exercise of stock options | 36 | 38 | 18 |
| Dividends paid | -1,068 | -1,060 | |
| Change in noncontrolling interests, net | 27 | -24 | -14 |
| Net cash used in financing activities | -1,452 | -3,117 | |
| Effect of exchange rate changes on cash and cash equivalents | 118 | -238 | |
| Net increase in cash and cash equivalents | 927 | 183 | |
| Cash and cash equivalents at the beginning of the reporting period | 15 | 1,837 | 1,654 |
| Cash and cash equivalents at the end of the reporting period | 15 | 2,764 | 1,837 |
Additional information on payments that are included in net cash provided by operating activities
Download(XLS, 35 KB)| January 1 to December 31, € in millions | Note | 2021 | 2020 |
|---|---|---|---|
| Received interest | 94 | 66 | |
| Paid interest | -517 | -627 | |
| Income taxes paid | -750 | -765 | |
| The following notes are an integral part of the consolidated financial statements. | |||